Caroline Solas

Summary

Country: France

Publications

  1. doi request reprint Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?
    Caroline Solas
    Aix Marseille University, CRO2 INSERM, UMR911, France
    AIDS 26:2193-9. 2012
  2. doi request reprint [Evidence-based therapeutic drug monitoring for efavirenz]
    Caroline Solas
    Laboratoire de Pharmacocinétique et Toxicologie, Hopital de la Timone, Marseille, France
    Therapie 66:197-205. 2011
  3. doi request reprint [Evidence-based therapeutic drug monitoring of atazanavir]
    Caroline Solas
    Laboratoire de Pharmacocinétique et Toxicologie, Hopital de la Timone, Marseille, France
    Therapie 66:213-9. 2011
  4. doi request reprint [Evidence-based therapeutic drug monitoring for ribavirine]
    Caroline Solas
    Laboratoire de Pharmacocinétique et Toxicologie, Hopital de la Timone, Marseille, France
    Therapie 66:221-30. 2011
  5. pmc Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig
    Antoine Roch
    Aix Marseille Univ, URMITE CNRS UMR 6236, 27 Boulevard Jean Moulin, 13005 Marseille, France
    Crit Care 15:R219. 2011
  6. pmc Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
    Caroline Solas
    Fédération de Pharmacologie, AP HM Hôpital La Timone, and Unité FRE CNRS 2737, Faculte de Pharmacie, AP HM Hôpital de la Conception, Marseille, France
    Br J Clin Pharmacol 64:353-62. 2007
  7. doi request reprint The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients
    Caroline Solas
    Laboratoire de Pharmacocinetique, Hôpital Universitaire de La Timone, Marseille, France
    J Acquir Immune Defic Syndr 48:177-80. 2008
  8. doi request reprint Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients
    Caroline Solas
    CHU La Timone, Federation de Pharmacologie et de Toxicologie, Marseille, France
    Ther Drug Monit 30:670-3. 2008
  9. pmc Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor
    Caroline Solas
    Department of Pharmacokinetics, AP HM Timone, Marseille, France
    Br J Clin Pharmacol 57:436-40. 2004
  10. doi request reprint Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity
    Romain Guilhaumou
    Aix Marseille Univ, CRO2, INSERM, UMR 911, 13385 Marseille, France
    Cancer Chemother Pharmacol 68:1633-8. 2011

Collaborators

Detail Information

Publications22

  1. doi request reprint Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?
    Caroline Solas
    Aix Marseille University, CRO2 INSERM, UMR911, France
    AIDS 26:2193-9. 2012
    ..To examine the impact of ribavirin and abacavir coadministration on hepatitis C virus (HCV) virological response and trough ribavirin plasma concentration (Cmin) in HIV-HCV coinfected patients...
  2. doi request reprint [Evidence-based therapeutic drug monitoring for efavirenz]
    Caroline Solas
    Laboratoire de Pharmacocinétique et Toxicologie, Hopital de la Timone, Marseille, France
    Therapie 66:197-205. 2011
    ..Non-randomized studies have reported the interest of efavirenz therapeutic drug monitoring to optimize viral response and prevent CNS toxicity, allowing to suggest a level of evidence "recommended" for efavirenz...
  3. doi request reprint [Evidence-based therapeutic drug monitoring of atazanavir]
    Caroline Solas
    Laboratoire de Pharmacocinétique et Toxicologie, Hopital de la Timone, Marseille, France
    Therapie 66:213-9. 2011
    ..Therefore, the level of evidence of the interest of atazanavir therapeutic drug monitoring is recommended...
  4. doi request reprint [Evidence-based therapeutic drug monitoring for ribavirine]
    Caroline Solas
    Laboratoire de Pharmacocinétique et Toxicologie, Hopital de la Timone, Marseille, France
    Therapie 66:221-30. 2011
    ..Therefore, the level of evidence of the therapeutic drug monitoring of ribavirin is recommended...
  5. pmc Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig
    Antoine Roch
    Aix Marseille Univ, URMITE CNRS UMR 6236, 27 Boulevard Jean Moulin, 13005 Marseille, France
    Crit Care 15:R219. 2011
    ..In the present study, we investigated the influence of hypovolaemic shock requiring fluid loading on the plasma and pulmonary pharmacokinetic parameters of caspofungin in the pig...
  6. pmc Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
    Caroline Solas
    Fédération de Pharmacologie, AP HM Hôpital La Timone, and Unité FRE CNRS 2737, Faculte de Pharmacie, AP HM Hôpital de la Conception, Marseille, France
    Br J Clin Pharmacol 64:353-62. 2007
    ..Using a population pharmacokinetic approach, we investigated the effect of several MDR1 and CYP3A5 polymorphisms on the pharmacokinetic parameters of indinavir in HIV-infected patients...
  7. doi request reprint The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients
    Caroline Solas
    Laboratoire de Pharmacocinetique, Hôpital Universitaire de La Timone, Marseille, France
    J Acquir Immune Defic Syndr 48:177-80. 2008
    ..To evaluate the predictive value of the genotypic inhibitory quotient (GIQ) on the atazanavir response in treatment-experienced HIV-1-infected patients...
  8. doi request reprint Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients
    Caroline Solas
    CHU La Timone, Federation de Pharmacologie et de Toxicologie, Marseille, France
    Ther Drug Monit 30:670-3. 2008
    ..This could therefore improve therapeutic drug monitoring interpretations and provide an interesting tool for correlation with virologic data...
  9. pmc Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor
    Caroline Solas
    Department of Pharmacokinetics, AP HM Timone, Marseille, France
    Br J Clin Pharmacol 57:436-40. 2004
    ....
  10. doi request reprint Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity
    Romain Guilhaumou
    Aix Marseille Univ, CRO2, INSERM, UMR 911, 13385 Marseille, France
    Cancer Chemother Pharmacol 68:1633-8. 2011
    ..We subsequently assessed the impact of ABCB1 polymorphisms on intracellular vincristine accumulation...
  11. ncbi request reprint High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen
    Caroline Solas
    Department of Pharmacokinetics, Timone Hospital, Marseille, France
    J Acquir Immune Defic Syndr 29:374-7. 2002
    ....
  12. pmc HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study
    Sophie Perrin
    INSERM UMR_S 910, Aix Marseille Universite, Marseille, France
    PLoS ONE 7:e53035. 2012
    ..The present report focuses on lamin A processing, a pathway known to be altered in systemic genetic progeroid syndromes...
  13. doi request reprint Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases
    Romain Guilhaumou
    INSERM U911, Faculte de Pharmacie, 27 Boulevard Jean Moulin, 13385 Marseille Cedex 5, France
    Cancer Chemother Pharmacol 68:1191-8. 2011
    ....
  14. doi request reprint Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples
    Sylvie Quaranta
    Laboratoire de Pharmacocinétique et Toxicologie, Hopital de la Timone, Marseille, France
    Ther Drug Monit 31:695-702. 2009
    ....
  15. doi request reprint Vertical transmission of multidrug-resistant Q151M human immunodeficiency virus type 1 strains
    Mireille Henry
    Laboratoire de Virologie, Fédération Hospitalière de Bactériologie Virologie Clinique et d Hygiène, CHRU Timone, Marseille, France
    Pediatr Infect Dis J 27:278-80. 2008
    ..Sustained virologic success was obtained in the infant with postnatal antiretroviral therapy optimized according to genotypic drug resistance testing and therapeutic drug monitoring...
  16. doi request reprint Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples
    Romain Guilhaumou
    Laboratoire de Pharmacocinétique et Toxicologie, Hopital de la Timone, 264 rue Saint Pierre, 13385 Marseille Cedex 5, France
    J Chromatogr B Analyt Technol Biomed Life Sci 878:423-7. 2010
    ..A rapid, specific and sensitive LC/MS/MS method for quantification of vincristine in human plasma was developed and is now successfully applied for pharmacokinetic studies in paediatric patients...
  17. pmc Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients
    Caroline Solas
    Laboratory of Pharmacokinetics, University Hospital, Marseilles, France
    Antimicrob Agents Chemother 47:238-43. 2003
    ..Further studies are required to clarify the role and clinical relevance of drug penetration in sanctuaries in terms of long-term efficacy and drug resistance...
  18. ncbi request reprint Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations
    Alain Lafeuillade
    Department of Infectious Diseases, General Hospital, Toulon, France
    HIV Clin Trials 3:27-35. 2002
    ..To study the presence of three HIV-1 protease inhibitors (PIs) in the cerebrospinal fluid (CSF), semen, and lymph nodes and to assess the correlations with residual viral replication in these compartments...
  19. ncbi request reprint Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen
    Catherine Tamalet
    AIDS 21:2551-2. 2007
  20. ncbi request reprint Highlights from the 13th International Symposium on HIV and Emerging Infectious Diseases (ISHEID)
    Alain Lafeuillade
    Department of Infectious Diseases, Hôpital Chalucet, Rue Chalucet, F 83056 Toulon, France
    HIV Clin Trials 5:305-22. 2004
  21. ncbi request reprint Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy
    Stéphanie Basso
    J Acquir Immune Defic Syndr 31:115-7. 2002
  22. ncbi request reprint Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population
    Sylvie Quaranta
    FRE CNRS 2737, Faculté de Pharmacie de Marseille, 27 Boulevard Jean Moulin, 13385 Marseille Cedex 5, France
    Toxicol Lett 164:177-84. 2006
    ..These data confirmed that CYP3A5 gene is highly polymorphic. Furthermore, it will be now interesting to evaluate the impact of this polymorphism on the pharmacokinetic parameters of different drugs...